Finn forfatter "Vollan, Hans Kristian Moen"

Viser treff 1-2 av 2

  • The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer 
    Silwal-Pandit, Laxmi; Nord, Silje; Gythfeldt, Hedda; Møller, Elen Kristine; Fleischer, Thomas; Rødland, Einar Andreas; Krohn, Marit; Borgen, Elin; Garred, Øystein; Olsen, Tone; Vu, Phuong Ngoc Thi; Skjerven, Helle; Fangberget, Anne; Holmen, Marit Muri; Schlichting, Ellen; Wille, Elisabeth; Stokke, Mette Norberg; Vollan, Hans Kristian Moen; Kristensen, Vessela N.; Langerød, Anita; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Engebråten, Olav (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2017)
    Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated ...
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Høglander, Elen; Nord, Silje; Wedge, David C; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...